Drug Use and Addiction Research Programs - Research Projects
Active
- Assistance listing
- 93.DA1
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- Not on record
Program facts
- Treasury accounts
-
- 08-0293-2-0-261
- 08-0293-2-0-251
- 08-0293-2-0-241
- More information
Program details come from SAM.gov Assistance Listings. Updated .
About this program
The National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) supports basic, clinical, translational, and implementation research in substance use prevention, diagnosis, treatment, and drug overdose management under Assistance Listing 93.DA1, with recent grant awards dispersed as of the most recent closed opportunity.
NIDA funds research projects across a broad scope: development of new knowledge and approaches for preventing and treating drug use, misuse, and addiction, including related health outcomes such as HIV/AIDS. The program emphasizes both foundational science and practical implementation pathways. Award decisions weigh scientific and technical merit, research feasibility, potential contribution to the national drug use problem, and alignment with NIDA priorities. Review timelines range from 240 to 270 days from application submission for standard awards; AIDS-related applications are reviewed within 180 days of receipt. Renewals are determined at the opportunity level.
The portfolio operates predominantly as Project Grants, the primary vehicle through which NIDA distributes research funding. Grant awards flow directly from NIDA to recipient institutions following concurrence from the National Advisory Council on Drug Abuse and scientific peer review by Scientific Review Groups.
Eligible applicant organizations are specified at the individual NOFO level; the source does not enumerate a standard list. Recipients (excluding federal institutions) are subject to audit requirements under 2 CFR Part 200, Subpart F, and the NIH Grants Policy Statement. Financial records must be retained for at least three years, or longer if audit findings remain unresolved.
The source does not provide recent grant award examples, portfolio-level funding concentration data, current funding opportunity details, or typical award magnitudes. Current or near-term NOFOs are not listed in the source material. Organizations assessing pursuit under this program should review active opportunities on Grants.gov and consult NIDA's website for current solicitations and award amounts.
Objective and description
- Objective
To support basic, clinical, translational, and implementation research in the field of substance use. To develop new knowledge and approaches for the prevention, diagnosis, and treatment of drug use, misuse, and addiction, drug overdose, and related
- Description
To support basic, clinical, translational, and implementation research in the field of substance use. To develop new knowledge and approaches for the prevention, diagnosis, and treatment of drug use, misuse, and addiction, drug overdose, and related health outcome, including HIV/AIDS.
Eligibility
- Applicant eligibility
Eligible organizations determined at the NOFO level
How to apply
- Criteria for selecting proposals
The following considerations will be used in determining projects to be funded: (1) Scientific and technical merit; (2) the feasibility of the research; (3) potential contribution to the national drug use problem; and (4) relevance to NIDA priorities.
- Award procedure
Grants with which the National Advisory Council on Drug Abuse has concurred with the recommendations of the Scientific Review Groups and approved by NIDA for payment are awarded directly by NIDA to the applicant institution.
- Time to approval or disapproval
From 240 to 270 days from submission of grant application. For AIDS applications the range will not exceed 180 days from cited receipt date
- Renewals
Renewals are determined at the NOFO level.
- Appeals
A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page https://grants.nih.gov/grants/guide/notice-files/not-od-11-064.html, https://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-101.html and https://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-003.html
Quick answers
What is Assistance Listing 93.DA1?
Assistance Listing 93.DA1 is Drug Use and Addiction Research Programs - Research Projects, a federal grant program run by National Institutes of Health (Department of Health and Human Services).
What is the CFDA number for Drug Use and Addiction Research Programs - Research Projects?
Its CFDA number is 93.DA1: Assistance Listing numbers were called CFDA numbers before 2018.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program